"[
ABSTRAKPendahuluan: Osteopontin merupakan salah satu penanda molekuler hipoksia
endogen tumor. Hipoksia adalah salah satu faktor yang menentukan agresifitas
penyakit. Kadar osteopontin tinggi pada berbagai keganasan termasuk glioma
maligna. Peningkatan kadar osteopontin akan menyebabkan respon terapi berkurang.
Penelitian ini bertujuan untuk mengetahui korelasi antara kadar osteopontin praradiasi
dengan respon radiasi pada glioma maligna.
Metode: Penelitian ini merupakan studi retrospektif kohort terhadap 15 pasien
maligna glioma yang menjalani terapi radiasi dari juli 2004 sampai mei 2015 di
RSUPN. DR. Cipto Mangunkusumo. Osteopontin diperiksa menggunakan metode
ELISA dari sampel parafin blok. Volume tumor dihitung dari CT scan atau MRI
berdasarkan pengukuran volume tiga dimensi. Respon tumor dinilai dengan
membandingkan volume tumor sebelum dan sesudah radiasi dengan menggunakan
CT dan MRI.
Hasil: Didapatkan rerata kadar osteopontin sebesar 0,49 ± 0,45 ng/ml, rerata
persentase perubahan volume tumor 8,59 ± 54,22 %. Volume tumor yang membesar
60%. Tumor yang progresif sebesar 26,7%. Secara keseluruhan terdapat korelasi
negatif lemah yang tidak bermakna ( r -0,39 dan p 0,146 ) antara kadar osteopontin
dengan respon radiasi. Terdapat korelasi positif kuat yang tidak bermakna ( r +0,68
dan p 0,219 ) antara kadar osteopontin dengan respon radiasi pada kelompok yang
menggunakan kemosensitizer temozolamide.
Kesimpulan: Terdapat korelasi negatif lemah yang tidak bermakna antara kadar
osteopontin dengan respon radiasi. Terdapat korelasi positif kuat yang tidak
bermakna antara kadar osteopontin dengan respon radiasi pada kelompok yang
menggunakan kemosensitizer temozolamide.
ABSTRACTIntroduction : Osteopontin is an endogenous molecular marker of tumor hypoxia,
which is one of factors that determine the aggressiveness of the disease. Increased
level of osteopontin will decrease therapeutic response which will eventually
influence the success of therapy.The purpose of this study is to determine the
correlation between osteopontin level and radiation response in malignant glioma.
Method : This is a retrospective cohort study of 15 malignant glioma patients who
underwent radiation from July 2004 to May 2015 at Cipto Mangunkusumo Hospital.
Osteopontin level was measured with ELISA from paraffin embedded tissue. Tumor
volume was calculated by measuring three dimensional volume of tumor imaging
from CT or MRI. Tumor response was evaluated by comparing pre-irradiation with
post-irradiation tumor volume seen in CT and MRI.
Result : The mean osteopontin level was 0.49 ± 0.45 ng/ml and the mean percentage
of change in tumor volume was 8.59 ± 54.22 %. Enlargement of tumor volume was
60 %. Progressive disease was found in 26.7 % of patients. Overall, there was an
insignificant weak negative correlation (r -0.39 and p 0.146) between level of
osteopontin and radiation response. There was an insignificant strong positive
correlation (r +0.68 and p 0.219) between level of osteopontin and radiation response
in the group that received radiation therapy concurrent with temozolamide.
Conclusion : Overall, there was an insignificant weak negative correlation between
level of osteopontin and radiation response. In the group that received radiation
therapy concurrent with temozolamide, there was an insignificant strong positive
correlation between level of osteopontin and radiation response, Introduction : Osteopontin is an endogenous molecular marker of tumor hypoxia,
which is one of factors that determine the aggressiveness of the disease. Increased
level of osteopontin will decrease therapeutic response which will eventually
influence the success of therapy.The purpose of this study is to determine the
correlation between osteopontin level and radiation response in malignant glioma.
Method : This is a retrospective cohort study of 15 malignant glioma patients who
underwent radiation from July 2004 to May 2015 at Cipto Mangunkusumo Hospital.
Osteopontin level was measured with ELISA from paraffin embedded tissue. Tumor
volume was calculated by measuring three dimensional volume of tumor imaging
from CT or MRI. Tumor response was evaluated by comparing pre-irradiation with
post-irradiation tumor volume seen in CT and MRI.
Result : The mean osteopontin level was 0.49 ± 0.45 ng/ml and the mean percentage
of change in tumor volume was 8.59 ± 54.22 %. Enlargement of tumor volume was
60 %. Progressive disease was found in 26.7 % of patients. Overall, there was an
insignificant weak negative correlation (r -0.39 and p 0.146) between level of
osteopontin and radiation response. There was an insignificant strong positive
correlation (r +0.68 and p 0.219) between level of osteopontin and radiation response
in the group that received radiation therapy concurrent with temozolamide.
Conclusion : Overall, there was an insignificant weak negative correlation between
level of osteopontin and radiation response. In the group that received radiation
therapy concurrent with temozolamide, there was an insignificant strong positive
correlation between level of osteopontin and radiation response]"
